Azitra, Inc. (AZTR)

Market Cap	3.82M
Revenue (ttm)	n/a
Net Income (ttm)	-11.11M
Shares Out	10.20M
EPS (ttm)	-4.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	288,305
Open	0.3560
Previous Close	0.3569
Day's Range	0.3514 - 0.3770
52-Week Range	0.3024 - 4.3290
Beta	-1.70
Analysts	Strong Buy
Price Target	4.00 (+968.66%)
Earnings Date	Nov 12, 2025

About AZTR

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epider...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2023
• Employees: 12
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: AZTR
• Website: https://azitrainc.com

Financial Performance

In 2024, Azitra's revenue was $7,500, a decrease of -98.91% compared to the previous year's $686,000. Losses were -$8.97 million, -29.05% less than in 2023.

Analyst Summary

According to one analyst, the rating for AZTR stock is "Strong Buy" and the 12-month stock price target is $4.0.

Price Target

$4.0

(968.66% upside)

Analyst Consensus: Strong Buy